Skip header and navigation

Refine By

205 records – page 1 of 21.

The 2000 tularemia outbreak: a case-control study of risk factors in disease-endemic and emergent areas, Sweden.

https://arctichealth.org/en/permalink/ahliterature188853
Source
Emerg Infect Dis. 2002 Sep;8(9):956-60
Publication Type
Article
Date
Sep-2002
Author
Henrik Eliasson
Johan Lindbäck
J Pekka Nuorti
Malin Arneborn
Johan Giesecke
Anders Tegnell
Author Affiliation
Orebro University Hospital, Sweden.
Source
Emerg Infect Dis. 2002 Sep;8(9):956-60
Date
Sep-2002
Language
English
Publication Type
Article
Keywords
Agriculture
Animals
Bites and Stings - microbiology
Case-Control Studies
Cat Diseases - microbiology - transmission
Cats
Culicidae - microbiology
Disease Outbreaks
Disease Vectors
Female
Francisella tularensis
Humans
Lymph Nodes - pathology
Male
Multivariate Analysis
Odds Ratio
Questionnaires
Risk factors
Sweden - epidemiology
Tularemia - epidemiology - pathology - transmission
Abstract
A widespread outbreak of tularemia in Sweden in 2000 was investigated in a case-control study in which 270 reported cases of tularemia were compared with 438 controls. The outbreak affected parts of Sweden where tularemia had hitherto been rare, and these "emergent" areas were compared with the disease-endemic areas. Multivariate regression analysis showed mosquito bites to be the main risk factor, with an odds ratio (OR) of 8.8. Other risk factors were owning a cat (OR 2.5) and farm work (OR 3.2). Farming was a risk factor only in the disease-endemic area. Swollen lymph nodes and wound infections were more common in the emergent area, while pneumonia was more common in the disease-endemic area. Mosquito bites appear to be important in transmission of tularemia. The association between cat ownership and disease merits further investigation.
Notes
Cites: Scand J Infect Dis. 1985;17(4):371-54089543
Cites: JAMA. 1985 Nov 22-29;254(20):2922-54057512
Cites: J Vet Diagn Invest. 1990 Jul;2(3):239-412094456
Cites: J Am Vet Med Assoc. 1991 Dec 1;199(11):1602-51778744
Cites: Eur J Clin Microbiol Infect Dis. 1992 May;11(5):447-81425715
Cites: J Hand Surg Am. 1993 Jan;18(1):132-48423298
Cites: Clin Infect Dis. 1993 Apr;16(4):472-58513049
Cites: West J Med. 1993 Jun;158(6):619-228337864
Cites: N C Med J. 1995 Jul;56(7):314-77643926
Cites: FEMS Immunol Med Microbiol. 1996 Mar;13(3):201-48861029
Cites: J Am Vet Med Assoc. 1998 Jan 1;212(1):81-39426784
Cites: N Engl J Med. 2001 Nov 29;345(22):1601-611757506
Cites: J Infect Dis. 1970 Mar;121(3):357-95415053
Cites: Scand J Infect Dis. 1971;3(1):7-165099427
Cites: J Infect Dis. 1975 Feb;131(2):197-91167886
Cites: Scand J Infect Dis. 1984;16(3):285-906149615
Cites: Medicine (Baltimore). 1985 Jul;64(4):251-693892222
Cites: Am J Epidemiol. 1991 May 15;133(10):1032-82035503
PubMed ID
12194773 View in PubMed
Less detail

Accuracy of preoperative T and N staging in colon cancer--a national population-based study.

https://arctichealth.org/en/permalink/ahliterature277228
Source
Colorectal Dis. 2016 Jan;18(1):73-9
Publication Type
Article
Date
Jan-2016
Author
A. Sjövall
L. Blomqvist
M. Egenvall
H. Johansson
A. Martling
Source
Colorectal Dis. 2016 Jan;18(1):73-9
Date
Jan-2016
Language
English
Publication Type
Article
Keywords
Adenocarcinoma - pathology - radiography - surgery
Adolescent
Adult
Aged
Aged, 80 and over
Colonic Neoplasms - pathology - radiography - surgery
Female
Humans
Lymph Nodes - pathology - radiography
Male
Middle Aged
Neoplasm Staging
Preoperative Period
Sweden
Tomography, X-Ray Computed
Young Adult
Abstract
To select patients for neoadjuvant therapy in colon cancer, there is a need to improve pre-therapeutic locoregional staging. There are now data showing that the TN stage can be adequately assessed by preoperative CT in dedicated centres. In Sweden the use of preoperative CT of the abdomen for staging of the primary tumour is increasing. The aim of this study was to determine to what extent the preoperatively reported radiological TN stage correlates with the histopathological TN stage in an entire population.
Data were collected on the preoperative cTN stage according to the radiologist and postoperative pTN stage according to the pathologist on all patients operated on for colon cancer in Sweden 2007-2010. The correlation between cTN stage and pTN stage was calculated using kappa statistics.
T stage was compared in 4373 patients with cT and pT stage. The correlation coefficient was 0.44, indicating fair agreement. The cN and pN correlation coefficient was 0.28, indicating a slight correlation. There was no difference in correlation related to age, gender, tumour location, body mass index or emergent vs elective surgery. A slight difference was seen between different geographical regions.
Preoperative CT in an unselected population does not result in an accurate cTN staging as previously reported from dedicated centres. To achieve adequate preoperative cTN staging nationally, the education of radiologists and optimization of the radiological method will be necessary.
PubMed ID
26291535 View in PubMed
Less detail

Acute myeloid leukemia with inv(16)(p13q22): involvement of cervical lymph nodes and tonsils is common and may be a negative prognostic sign.

https://arctichealth.org/en/permalink/ahliterature18894
Source
Am J Hematol. 2002 Sep;71(1):15-9
Publication Type
Article
Date
Sep-2002
Author
R. Billström
T. Ahlgren
A N Békássy
C. Malm
T. Olofsson
M. Höglund
F. Mitelman
B. Johansson
Author Affiliation
Department of Hematology, Lund University Hospital, Lund, Sweden. rolf.billstrom@skane.se
Source
Am J Hematol. 2002 Sep;71(1):15-9
Date
Sep-2002
Language
English
Publication Type
Article
Keywords
Adult
Aged
Central Nervous System - pathology
Child
Child, Preschool
Chromosomes, Human, Pair 16 - genetics - ultrastructure
Female
Humans
Inversion, Chromosome
Leukemia, Myelomonocytic, Acute - epidemiology - genetics - pathology
Leukemic Infiltration
Lymph Nodes - pathology
Male
Prognosis
Research Support, Non-U.S. Gov't
Retrospective Studies
Tonsil - pathology
Treatment Outcome
Abstract
Acute myeloid leukemia (AML) with inv(16)(p13q22) or the variant t(16;16)(p13;q22), is strongly associated with the FAB subtype M4Eo. A high incidence of CNS involvement was reported in the 1980s, but otherwise little is known about the pattern of extamedullary leukemia (EML) manifestations in this AML type. We have compiled clinical and cytogenetic data on 27 consecutive AML cases with inv(16)/t(16;16) from southern Sweden. In general, these AMLs displayed the clinical features that have previously been described as characteristic for this disease entity: low median age, hyperleukocytosis, M4Eo morphology, and a favorable prognosis. However, CNS leukemia was only seen in relapse in one patient diagnosed in 1980, whereas the most common EML manifestation in our series was lymphadenopathy (5/27, 19%), most often cervical with or without gross tonsillar enlargement. A review of previously published, clinically informative cases corroborates that lymphadenopathy, with preference for the cervical region, is the most common EML at diagnosis in inv(16)-positive AML (58/175, 33%). CNS leukemia, on the other hand, has been reported in only 17% of the cases, mostly in the relapse setting, with a diminishing frequency over time, possibly due to protective effects of high-dose cytarabine. Other reported EML sites include the scalp, ovaries, and the intestine. Cervicotonsillar EML was in our series associated with a shorter duration of first remission, (P
PubMed ID
12221668 View in PubMed
Less detail

Adenocarcinoma of the prostate in perspective.

https://arctichealth.org/en/permalink/ahliterature248080
Source
Can Med Assoc J. 1978 Nov 4;119(9):1077-84
Publication Type
Article
Date
Nov-4-1978
Author
A W Bruce
D E Mahan
Source
Can Med Assoc J. 1978 Nov 4;119(9):1077-84
Date
Nov-4-1978
Language
English
Publication Type
Article
Keywords
Acid Phosphatase - blood
Adenocarcinoma - therapy
Aged
Bone Neoplasms - diagnosis
Clinical Enzyme Tests
Ethinyl Estradiol - therapeutic use
Evaluation Studies as Topic
Humans
Immunologic Techniques
Lymph Nodes - pathology
Male
Middle Aged
Neoplasm Metastasis
Neoplasm Staging
Ontario
Prostate - pathology
Prostatic Neoplasms - pathology - therapy
Radiotherapy, High-Energy
Seminal Vesicles - pathology
Abstract
Adenocarcinoma of the prostate is responsible for one of every nine deaths from cancer in Canada. In this review epidemiologic factors are considered and current staging systems are outlined. The American Urological System is recommended for staging because of its ability to reflect changes in the understanding of the biologic behaviour of this neoplasm. The adoption of a quantitative grading scheme is suggested to complement the information obtained from the staging assessment. The routes of spread of this disease, along with the procedures used to assess metastatic involvement, are described. Immunologic methods for the analysis of prostatic acid phosphatase have been shown to be superior to the enzymatic methods previously used, and the role of the new techniques is discussed. Emphasis is placed on radiotherapy and endocrine therapy for the treatment of this neoplasm, and the concept of withholding endocrine therapy until symptoms appear is discussed. Potential future developments in this field are considered.
Notes
Cites: J Urol. 1976 Jan;115(1):86-81107604
Cites: Urol Clin North Am. 1975 Feb;2(1):105-241128746
Cites: Cancer Res. 1975 Sep;35(9):2446-521170944
Cites: J Urol. 1976 Apr;115(4):409-121263317
Cites: J Pathol Bacteriol. 1953 Jul;66(1):91-313109621
Cites: Cancer. 1954 Jul;7(4):690-70313172685
Cites: Calif Med. 1954 Nov;81(5):308-1313209358
Cites: Cancer Res. 1954 Nov;14(10):718-2413209548
Cites: J Am Med Assoc. 1956 Mar 10;160(10):838-913295029
Cites: Am J Med. 1956 Nov;21(5):697-71313362301
Cites: J Urol. 1959 Jan;81(1):194-613631798
Cites: Am J Med. 1959 Dec;27:902-1013845841
Cites: Ann Surg. 1940 Jul;112(1):138-4917857618
Cites: J Urol. 1977 Apr;117(4):459-63321808
Cites: Cancer. 1978 May;41(5):1788-93348296
Cites: J Urol. 1973 Aug;110(2):242-44124679
Cites: CA Cancer J Clin. 1974 Sep-Oct;24(5):282-84138838
Cites: J Urol. 1978 Jan;119(1):94-8413938
Cites: J Urol. 1967 Dec;98(6):686-924169732
Cites: J Urol. 1968 Jan;99(1):79-864170153
Cites: Invest Urol. 1968 Jan;5(4):371-84170388
Cites: J Urol. 1970 Apr;103(4):462-64191242
Cites: Br J Urol. 1973 Dec;45(6):668-774359746
Cites: Surg Clin North Am. 1974 Aug;54(4):887-954428321
Cites: Cancer. 1973 Nov;32(5):1126-304585929
Cites: S Afr Med J. 1973 Feb 3;47(5):179-804684246
Cites: Cancer. 1973 Nov;32(5):1092-54757906
Cites: J Urol. 1974 May;111(5):644-64823973
Cites: Cancer. 1972 Apr;29(4):941-55017363
Cites: J Urol. 1972 Dec;108(6):897-9005082743
Cites: Can Med Assoc J. 1971 Jul 10;105(1):71-25088479
Cites: Radiology. 1971 Feb;98(2):343-515099838
Cites: Br J Urol. 1971 Oct;43(5):520-25118130
Cites: N Y State J Med. 1966 Feb 1;66(3):351-55216613
Cites: Can Med Assoc J. 1970 Aug 15;103(4):372-35447717
Cites: Radiol Clin North Am. 1970 Aug;8(2):259-705453484
Cites: Radiology. 1971 Apr;99(1):192-65548678
Cites: J Natl Cancer Inst. 1968 Jan;40(1):43-685635018
Cites: Cancer. 1969 Jan;23(1):24-345763258
Cites: J Urol. 1965 Nov;94(5):604-65846201
Cites: J Urol. 1967 Jun;97(6):1075-76067543
Cites: Cancer. 1978 Apr;41(4):1433-9639003
Cites: Urology. 1978 May;11(5):542675916
Cites: Urology. 1978 Jun;11(6):599-602675926
Cites: Cancer Treat Rep. 1977 Mar-Apr;61(2):173-8068821
Cites: Cancer Treat Rep. 1977 Mar-Apr;61(2):193-20068822
Cites: Cancer Treat Rep. 1977 Mar-Apr;61(2):205-1068824
Cites: N Engl J Med. 1977 Dec 22;297(25):1357-6173133
Cites: Invest Urol. 1978 Jan;15(4):319-2375196
Cites: CA Cancer J Clin. 1975 Jan-Feb;25(1):2-8804962
Cites: Annu Rev Med. 1975;26:567-88807150
Cites: J Urol. 1977 Feb;117(2):197-8833967
Cites: Arch Androl. 1978 May;1(3):227-3383815
Cites: Arch Androl. 1978 May;1(3):235-983816
Cites: J Urol. 1977 Mar;117(3):319-22839593
Cites: Urology. 1977 Mar;9(3):273-5841802
Cites: Radiology. 1977 May;123(2):319-22847193
Cites: Cancer Treat Rep. 1977 Mar-Apr;61(2):223-5872130
Cites: J Urol. 1977 Nov;118(5):733-8916091
Cites: Urology. 1976 Jun;7(6):598-601936380
Cites: Urology. 1976 Jun;7(6):602-10936381
Cites: J Urol. 1976 Aug;116(2):206-10950705
Cites: J Urol. 1976 Aug;116(2):211-3950706
Cites: Cancer. 1976 Nov;38(5):2078-87991119
PubMed ID
105800 View in PubMed
Less detail

Adjuvant tamoxifen in postmenopausal high-risk breast cancer patients: present status of Danish Breast Cancer Cooperative Group trials.

https://arctichealth.org/en/permalink/ahliterature26492
Source
NCI Monogr. 1986;(1):115-8
Publication Type
Article
Date
1986
Author
H T Mouridsen
A P Andersen
H. Brincker
P. Dombernowsky
C. Rose
K W Andersen
Source
NCI Monogr. 1986;(1):115-8
Date
1986
Language
English
Publication Type
Article
Keywords
Aged
Axilla
Breast Neoplasms - drug therapy - mortality - radiotherapy
Clinical Trials
Denmark
Female
Humans
Lymph Nodes - pathology
Mastectomy
Menopause
Middle Aged
Receptors, Estrogen - drug effects - physiology
Retrospective Studies
Risk
Tamoxifen - therapeutic use
Abstract
The aim of the present study was to analyze the efficacy of adjuvant tamoxifen (TAM) in postmenopausal patients with high-risk breast cancer. The primary surgical treatment was total mastectomy with axillary sampling. There were 1,650 eligible patients; 829 were randomized to receive postoperative radiotherapy (RT) and 821, to receive RT + TAM (10 mg three times daily for 1 yr). The 2 groups were identical with respect to age, tumor size, number of positive lymph nodes, degree of anaplasia, and estrogen and progesterone receptor content. Overall recurrence-free survival at 6 years was 39% in the RT group, compared to 48% in the RT + TAM group (P = 0.0008), but there was no significant difference in survival (P = 0.14). From retrospective analyses of recurrence-free survival according to prognostic variables, it appears that 4 subgroups of patients benefited from adjuvant TAM: those less than 69 years of age, those with 4 or more positive nodes, those with grade I-II tumors, and those with high estrogen receptor values (greater than 100 fmol/mg cytosol protein).
PubMed ID
3534583 View in PubMed
Less detail

Adverse reactions in healthy and immunocompromised children under six years of age vaccinated with the Danish BCG vaccine, strain Copenhagen 1331: implications for the vaccination policy in Sweden.

https://arctichealth.org/en/permalink/ahliterature36048
Source
Acta Paediatr. 1993 Dec;82(12):1043-52
Publication Type
Article
Date
Dec-1993
Author
V. Romanus
A. Fasth
P. Tordai
B E Wiholm
Author Affiliation
Department of Epidemiology, National Bacteriological Laboratory, Solna, Sweden.
Source
Acta Paediatr. 1993 Dec;82(12):1043-52
Date
Dec-1993
Language
English
Publication Type
Article
Keywords
Age Factors
BCG Vaccine - adverse effects
Child
Child, Preschool
Health Policy
Humans
Hypertrophy - epidemiology
Immunocompromised Host
Immunologic Deficiency Syndromes - diagnosis
Infant
Infant, Newborn
Lymph Nodes - pathology
Retrospective Studies
Risk
Sweden - epidemiology
Vaccination - adverse effects
Abstract
A retrospective analysis of the adverse reactions reported between 1979 and 1991, in the 139,000 children under six years of age vaccinated in Sweden with the Danish BCG vaccine, strain Copenhagen 1331, showed an incidence of 1.9 per 1000 vaccinated children. Regional lymphoglandular swellings and/or abscesses were most commonly reported in 1.4 per 1000. Serious, disseminated, BCG infections developed in four infants vaccinated neonatally. Three of the infants suffered from severe, combined, immunodeficiency syndrome, undiagnosed at the time of vaccination. The incidence of severe, combined, immunodeficiency syndrome was higher in the BCG-vaccinated population (4 per 100,000 infants vaccinated within a year of their births), compared with all newborns in Sweden (1 per 100,000). The mean age at the onset of symptoms was 2.4 months for the seven non-BCG-vaccinated infants versus 1.3 months for the four BCG-vaccinated ones, while the immunodeficiency syndrome was diagnosed at an average age of 7.6 months in those who were not vaccinated versus 5.3 months in those BCG-vaccinated. It is recommended that the selective BCG vaccination of infants at high risk of exposure to tuberculosis should be postponed to six months of age to reduce the risk of inoculating infants suffering from immunodeficiency syndromes.
PubMed ID
8155923 View in PubMed
Less detail

Aggressive Kaposi's sarcoma in children: a case report.

https://arctichealth.org/en/permalink/ahliterature8462
Source
Turk J Pediatr. 1989 Oct-Dec;31(4):297-303
Publication Type
Article
Author
E S Akman
U. Ertem
V. Tankal
A. Pamir
A M Tuncer
O. Uluoglu
Author Affiliation
Department of Pediatric Hematology, Dr. Sami Ulus Children's Hospital, Ankara.
Source
Turk J Pediatr. 1989 Oct-Dec;31(4):297-303
Language
English
Publication Type
Article
Keywords
Child, Preschool
Humans
Lymph Nodes - pathology
Lymphatic Metastasis
Male
Sarcoma, Kaposi - mortality - pathology
Abstract
A three-year-old-boy with generalized Kaposi's sarcoma (KS) is presented. The child died of progressive pulmonary insufficiency on the eighteenth day of the course of his illness, the tenth hospital day. On postmortem examination diffuse KS infiltration was observed in the respiratory and gastrointestinal tracts, lymph nodes, liver, spleen and thymus. The patient was considered to be a case of KS unrelated to AIDS because of his negative HTLV-III antibody and epidemiologic characteristics, and therefore was believed to have primary aggressive KS.
PubMed ID
2486429 View in PubMed
Less detail

Aggressiveness of breast cancers found with and without screening.

https://arctichealth.org/en/permalink/ahliterature224308
Source
BMJ. 1992 Feb 22;304(6825):467-9
Publication Type
Article
Date
Feb-22-1992
Author
P J Klemi
H. Joensuu
S. Toikkanen
J. Tuominen
O. Räsänen
J. Tyrkkö
I. Parvinen
Author Affiliation
Turku University Hospital, Finland.
Source
BMJ. 1992 Feb 22;304(6825):467-9
Date
Feb-22-1992
Language
English
Publication Type
Article
Keywords
Adult
Aged
Breast Neoplasms - chemistry - pathology
Breast Self-Examination
Cell Count
Cohort Studies
Female
Finland
Humans
Lymph Nodes - pathology
Mammography
Mass Screening
Middle Aged
Mitotic Index
Receptors, Estrogen - analysis
Receptors, Progesterone - analysis
Abstract
To examine how breast cancers found by mammographic screening differ from those found outside screening.
Comparative cohort study.
Turku, southwestern Finland.
126 women aged 40-74 years with breast cancer detected during the first round of mammographic screening in 1987-90 and 125 women within the same age range with breast cancer detected outside screening during the same period.
Primary tumour size, axillary nodal status, histological features, oestrogen and progesterone receptor concentrations, ploidy, and S phase fraction.
Compared with the controls women with cancers detected by screening had a smaller primary tumour (57 (46%) screened v 11 (10%) controls had tumours less than or equal to 11 mm in diameter, p less than 0.0001), and less often had axillary nodal metastases (104 (83%) screened v 71 (57%) controls node negative, p less than 0.0001). After adjustment for the smaller size of the primary tumour compared with control cancers, those cancers detected by screening were less likely to have axillary nodal metastases (odds ratio 0.44, 95% confidence interval 0.23 to 0.84), poor histological differentiation (0.20, 0.08 to 0.49), high mitotic counts (0.38, 0.15 to 0.97), tumour necrosis (0.45, 0.22 to 0.93) or to be of the ductal histological type (0.46, 0.22 to 0.95). They had low oestrogen receptor (0.29, 0.12 to 0.70) and progesterone receptor (0.35, 0.17 to 0.92) concentrations less often and had smaller S phase fractions (0.72, 0.55 to 0.96) than control cancers.
Even after adjustment for the smaller size of screen detected breast cancers, their histological and cytometric features suggest low malignant potential. They may also be less likely to metastasise to axillary lymph nodes than cancers found outside screening.
Notes
Cites: Br J Cancer. 1991 Sep;64(3):588-921911203
Cites: Lancet. 1990 Feb 3;335(8684):241-61967717
Cites: Cytometry. 1989 Jul;10(4):410-62766887
Cites: Lancet. 1985 Apr 13;1(8433):829-322858707
Cites: Natl Cancer Inst Monogr. 1985 May;67:65-744047153
Cites: J Histochem Cytochem. 1983 Nov;31(11):1333-56619538
Cites: Br J Cancer. 1984 Jun;49(6):709-156733019
Cites: APMIS. 1990 Nov;98(11):1005-142248765
Cites: Br J Cancer. 1987 Dec;56(6):814-92829956
Cites: BMJ. 1988 Oct 15;297(6654):943-83142562
Cites: Int J Cancer. 1988 Nov 15;42(5):697-7023182106
Cites: Lancet. 1984 Jun 2;1(8388):1222-46144933
Comment In: BMJ. 1992 May 23;304(6838):1377-81611345
PubMed ID
1547414 View in PubMed
Less detail

[Analysis of local lymphogenic spreading of malignant adrenal tumors]

https://arctichealth.org/en/permalink/ahliterature17542
Source
Lik Sprava. 2004 Apr-May;(3-4):64-6
Publication Type
Article
Author
A M Kvacheniuk
Source
Lik Sprava. 2004 Apr-May;(3-4):64-6
Language
Ukrainian
Publication Type
Article
Keywords
Adrenal Gland Neoplasms - pathology - surgery
English Abstract
Female
Humans
Lymph Nodes - pathology
Lymphatic Metastasis
Male
Abstract
The effectivity of the treatment of malignant adrenal tumors (MAT) depends on primary complete tumor resection with its regional metastases (RM). The possible regional metastases of malignant adrenal tumors in 257 patients have been studied. One third of the patients were diagnosed with regional metastases. Practically, almost all the patients had malignant adrenal tumors metastasizing lymphogenically. It was noted that independently of the tumors' localisation, morphological structure, the regional metastases more often were found in lymph nodes of the renal hilus, paranephral and paraaortical cellular tissue. Consequently, lymph nodes of the renal hilus, paranephral and paraaortical cellular tissue as well as of back muscle should be revised during radical operations in patients with malignant adrenal tumors.
PubMed ID
15318829 View in PubMed
Less detail

205 records – page 1 of 21.